Skip to main content

Oxidative Stress and Endothelial Dysfunction in Cardiovascular Disease: Mitochondria-Targeted Therapeutics

Buy Article:

$55.00 plus tax (Refund Policy)

Functional impairment of endothelial activity (endothelial dysfunction) precedes the development of cardiovascular diseases (CVD). This condition is a result of a reduced bioavailability of nitric oxide (NO), a well known vasodilator, which is mainly due to increased NO degradation caused by its reaction with reactive oxygen species (ROS). Although there are several conditions that contribute independently to endothelial dysfunction, such as hyperglycemia, insulin resistance, hyperinsulinemia and dyslipidemia, increased oxidative stress seems to play a key role. In addition to their original pharmacological properties, drugs used clinically at present, including anti-hypertension reagents, angiotensin receptor blockers and anti-hyperlipidemic reagents such as statins, protect various organs via anti-oxidative stress mechanims. Moreover, some substances with antioxidant properties, such as vitamin C or vitamin E, have been used to erradicate the oxidative stress associated with CVD. The results of the clinical trials employing anti-oxidative stress reagents in patients with CVD are contradictory, which could be a result of inadequate study design or selected targets. This review considers the process of endothelial dysfunction and CVD from a mitochondrial perspective and evaluates strategies currently under development for the targeted delivery of antioxidants or NO to mitochondria. It endorses the idea that selectively targeting specific antioxidants and NO donors to mitochondria is an effective strategy for modulating mitochondrial respiration and ROS production and protecting mitochondria against oxidative stress.





No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: Antioxidant; Mitochondrial dysfunction; N-acetyl cysteine (NAC); NITROGEN SPECIES (RONS); S-Nitrosothiols (SNOs); The Probucol Quantitative Regression Study (PQRST); angiotensin; antifibrinolitic; asymmetric dimethylargin-ine; atherosclerosis; bioavailability; cardiovas-cular diseases (CVD); cardiovascular dysfunction; carotenoids; cell necrosis; cytochrome; dyslipemia; dyslipidemia; electron transport chain (ETC); endothelial dysfunction; endothelium; endothelium, mitochondria; endothelium-dependent vasodilatation; fragmentation; glutathione peroxidases (GPx); hy-percholesterolemic; hydroxyeicosatetraenoic acids (HETEs; hydroxyocta-decaenoic acids (HODEs); hyperglycemia; hyperinsulinemia; insu-lin resistance; lactoferrin; lipid car-diolipin; lipoic acid; membrane depolarisation; metal-binding proteins; metal-lothionein; mitochondria; neurodegenerative diseases; neuroprotective; nitric oxide; nitroglycerine; obesity; oxidative; oxidative stress; proinflammatory; reactive oxygen species; reactive oxygen species (ROS); synaptosomes; tocopherols; transferrin; triphenylphosphonium (TPP); ubiquinol (MitoQ); vasoconstrictor; vitamin C; vitamin E

Document Type: Research Article

Publication date: 2010-11-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more